Revenue expanding at 45% annually demonstrates genuine early commercial traction, but negative free cash flow at 52% of revenue, a single confirmatory Phase 3 trial as the decisive catalyst, and 25% short interest mark this as a high-asymmetry situation where the upside scenario demands both clinical success and consistent execution.
Thesis pillars
- Concentrated Short Interest Overhang↑Improving
- Confirmatory Trial Single Asset Dependency↑Improving
- Revenue Growth Against Cash Consumption→Stable
- +2 more pillars — see the Why tab for full reasoning
Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $14.21: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10. Specifically: High short interest: 15%; Below-average business quality; Rich valuation.
Iovance Biotherapeutics is a commercial-stage biopharmaceutical company selling two products: Amtagvi® (lifileucel), the first approved one-time T cell therapy for a solid tumor cancer (advanced melanoma), and Proleukin® (aldesleukin), an IL-2 used in the Amtagvi regimen. The... Read more
Sell if holding. Engine safety override at $14.21: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10. Specifically: High short interest: 15%; Below-average business quality; Rich valuation. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.1/10, moderate confidence.
Passes 5/8 gates (clean insider activity, news boost analyst 0.50, earnings proximity 20d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: speculative.
About Iovance Biotherapeutics, Inc.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics commercially launched Amtagvi (lifileucel) — the first FDA-approved one-time T cell therapy for a solid tumor cancer — in the U.S. in Q2 2024, and sells Proleukin (aldesleukin) acquired from Clinigen in May 2023. The company reported a net loss of $391.0 million for the year ended December 31, 2025, with an accumulated deficit of $2.8 billion and $303.0 million in cash. Amtagvi is approved in the U.S. and Canada; potential approvals are pending in the UK and Australia in H1 2026 and Switzerland in 2027.
Iovance sells Amtagvi through a growing authorized treatment center (ATC) network, with revenue recognized upon patient infusion; Proleukin is sold to three main U.S. distributors and distributors outside the U.S. across three channels — use in the Amtagvi treatment regimen, use in manufacturing processes for cell therapies, and clinical and research settings. All Amtagvi manufacturing transferred to the Iovance Cell Therapy Center (iCTC) in Philadelphia after the Minaris contract terminated in Q1 2026; the iCTC is the sole FDA-approved facility with a centralized TIL manufacturing process and potential capacity for more than 5,000 patients annually. Proleukin supply comes from Boehringer Ingelheim Biopharmaceuticals GmbH under a supply agreement extended through December 31, 2028 with minimum annual vial commitments. The company pays royalties ranging from less than one to mid-single-digit percent of net sales to the NIH under a patent license agreement extended to August 2029.
Show full overview
The confirmatory Phase 3 trial TILVANCE-301 — randomizing approximately 670 frontline advanced melanoma patients — serves a dual purpose: establishing a registrational path for lifileucel combined with pembrolizumab and generating data to support full U.S. approval for Amtagvi in previously treated patients. The company withdrew an initial EU marketing authorization application in July 2025 and plans to resubmit a centralized MAA to the EMA in 2026; if the resubmission does not receive approval, the addressable patient population outside the U.S. and Canada could be materially constrained.
See also: Healthcare · Biotechnology
From Iovance Biotherapeutics, Inc.'s most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated 2026-10-15Recent Developments — Iovance Biotherapeutics, Inc.
Latest news
- NEWS IOVA Stock Slump Takes Wall Street, Retail By Surprise — Here’s Why - Stocktwits — Stocktwits negative
- NEWS IOVA Stock Quote Price and Forecast - CNN — CNN neutral
- NEWS IOVA Stock Quote Price and Forecast - cnn.com — cnn.com neutral
- NEWS Iovance Biotherapeutics, Inc. Stock 12‑Month Price Target Raised to $8.67, Implies 100% Upside - TradingView — TradingView positive
- NEWS Iovance Biotherapeutics, Inc. Stock 12‑Month Price Target Raised to $8.67, Implies 100% Upside - tradingview.com — tradingview.com positive
Generated 2026-10-15T11:47:13Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMProductAmtagvi® (lifileucel)10-K Item 1: 'Our top priority is to drive commercial success of Amtagvi® for previously treated advanced melanoma'
- HIGHpipelineTILVANCE-301 (Amtagvi confirmatory Phase 3)10-K Item 1: 'TILVANCE-301, is designed to support a registrational path for lifileucel ... to support full U.S. approval for Amtagvi® in post-anti-PD-1 advanced melanoma'
- MEDIUMSupplierBoehringer Ingelheim (Proleukin® manufacturer)10-K Item 1: 'manufacturing and supply agreement with Boehringer Ingelheim Biopharmaceuticals GmbH, to carry out the processing, manufacturing, and supply of Proleukin® in unlabeled vials'
Material Events(8-K, last 90d)
- 2026-03-20Item 5.02LOWBoard director Wendy Yarno gave notice March 17, 2026 she will retire and not stand for re-election at the June 2026 annual meeting. Will serve out current term. No disagreement with company operations, policies, or practices cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $14.21: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10. Specifically: High short interest: 15%; Below-average business quality; Rich valuation. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $13.22. Score 5.1/10, moderate confidence.
Take-profit target: $14.99 (-11.8% upside). Prior stop was $13.22. Stop-loss: $13.22.
Concentration risk — Pipeline: TILVANCE-301 (Amtagvi confirmatory Phase 3); Target reached (-11.8% upside); Quality below floor (3.1 < 4.0).
Iovance Biotherapeutics, Inc. trades at a P/E of N/A (forward -72.6). TrendMatrix value score: 1.8/10. Verdict: Sell.
15 analysts cover IOVA with a consensus score of 4.0/5. Average price target: $14.
What does Iovance Biotherapeutics, Inc. do?Iovance Biotherapeutics is a commercial-stage biopharmaceutical company selling two products: Amtagvi® (lifileucel),...
Iovance Biotherapeutics is a commercial-stage biopharmaceutical company selling two products: Amtagvi® (lifileucel), the first approved one-time T cell therapy for a solid tumor cancer (advanced melanoma), and Proleukin® (aldesleukin), an IL-2 used in the Amtagvi regimen. The company reported a net loss of $391.0 million in 2025 with $303.0 million in cash, scaling Amtagvi's authorized treatment center network while pursuing approvals in the UK, Australia, and EU.